This finding aligns with established clinical evidence in ovarian cancer: elevated serum HGF levels decrease upon chemotherapy [19], and tumor tissues exhibit a three-fold increase in IGF2 expression compared to normal tissue, correlating with poorer prognosis [20]. The gene discussed is IGF2; the disease is ovarian cancer.